store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Monomethyl lithospermate (Lithospermic acid monomethyl ester) has potential antiviral activity, alleviating ischemic stroke injury in vivo in middle cerebral artery occlusion mice by activating PI5K/Akt signaling and protecting oxygen-glucose deprivation/reoxygenation-induced SHSY-3Y cells in vitro. Monomethyl lithospermate could improve the viability of SHSY-5Y cells, inhibit mitochondrial membrane potential (MMOP) collapse, and inhibit cell apoptosis. Monomethyl lithospermate also reduced the level of oxidative stress in the brain tissue of middle artery occlusion (MCAO) rats and improved nerve damage in ischemic stroke (IS) rats.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | $ 358.00 | |
5 mg | Inquiry | $ 879.00 |
Description | Monomethyl lithospermate (Lithospermic acid monomethyl ester) has potential antiviral activity, alleviating ischemic stroke injury in vivo in middle cerebral artery occlusion mice by activating PI5K/Akt signaling and protecting oxygen-glucose deprivation/reoxygenation-induced SHSY-3Y cells in vitro. Monomethyl lithospermate could improve the viability of SHSY-5Y cells, inhibit mitochondrial membrane potential (MMOP) collapse, and inhibit cell apoptosis. Monomethyl lithospermate also reduced the level of oxidative stress in the brain tissue of middle artery occlusion (MCAO) rats and improved nerve damage in ischemic stroke (IS) rats. |
In vitro |
Monomethyl lithospermate (5, 10 and 20 μM; 12 h) increases cell viability of SHSY-5Y cells treated with oxygen-glucose deprivation and reperfusion (OGD/R).[1] Monomethyl lithospermate (20 μM; 12 h) reduces cell damage, mitochondrial membrane potential loss, and apoptosis in SHSY-5Y cells after hypoxia, glucose deprivation/reoxygenation.[1] Monomethyl lithospermate (5, 10 and 20 μM; 12 h) reduces ROS and intracellular oxidative stress in SHSY-5Y cells.[1] Monomethyl lithospermate (20 μM; 12 h) activates PI3K/AKT in SHSY-5Y cells.[1] |
In vivo |
Monomethyl lithospermate (72.4 μM/kg; oral; once daily for 14 days) improves neurological function and reduces cerebral infarct size in rats with ischemia-reperfusion (IR) 24 h after middle artery occlusion (MCAO); it can reduce MCAO rats reduce oxidative stress levels and inhibit neuronal apoptosis.[1] Monomethyl lithospermate improves ischemia-reperfusion-induced nerve damage by activating PI3K/AKT.[1] |
Synonyms | Lithospermic acid monomethyl ester |
Molecular Weight | 552.48 |
Formula | C28H24O12 |
CAS No. | 933054-33-2 |
store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Monomethyl lithospermate 933054-33-2 Cytoskeletal Signaling PI3K/Akt/mTOR signaling PI3K Akt Lithospermic acid monomethyl ester inhibitor inhibit